1.Clinical Progress in Platinum-based Chemotherapy for Esophageal Cancer
Chinese Journal of Clinical Oncology 2010;37(4):238-240
The esophagus carcinoma is one of the most common cancers in China. The therapy modes for esopha-gus carcinoma include surgery, radiotherapy and chemotherapy. Platinum-based combined chemotherapy has always been used in the treatment for esophagus carcinoma. In this article, we reviewed the application of platinum-based chemo-therapy in esophageal cancer in recent years. The efficacy of cisplatin in treating esophageal cancer has been proved. Cis-platin is used in neoadjuvant chemotherapy, adjuvant chemotherapy, concurrent chemo-radiotherapy and salvage chemo-therapy for esophageal cancer. Combined chemotherapy with 5-fluorouracil (5-FU) and cisplatin is regarded as the stan-dard regimen for esophageal cancer in concurrent chemoradiotherapy and salvage chemotherapy. Compared with cisplat-in, carboplatin causes lower rate of nephrotoxicity, reactions in the digestive tract and ototoxicity. But carboplatin does not have better effect. Patients with esopohageal adenocarcinoma show good clinical response to oxaliplatin and relatively sat-isfactory median survival. The rate of nephrotoxicity and reactions of digestive tract caused by cisplatin is lower. Oxaliplatin can lead to serious neurotoxicity. The therapeutic efficacy of nedaplatin is as good as that of cisplatin. Nedaplatin is used in concurrent chemoradiotherapy and salvage chemotherapy for esophageal squamous cell carcinoma. Compared with cispla-tin, nedaplatin can result in myelosuppression. Further research is warranted to explore whether nedaplatin can take place of cisplatin as the standard regimen. Lobaplatin combined with 5-fluorouracil (5-Fu) and leucovorin (CF) is effective and well tolerated for advanced esophagus carcinoma. The major toxicities noted are reversible bone marrow suppression and gastrointestinal tract reaction.
2.Research progresses in growth hormone receptor tumor biology effects
Parenteral & Enteral Nutrition 1997;0(03):-
The malignant tumor assumes the high metabolism condition,only the energy and protein inputing cannot effectively reduce the organism decomposition condition.But the growth hormone can enhance patient's curative effect and the tolerance in the complex therapy,while improving malnutrition and the negative nitrogen balance.The key point is the growth hormone receptor union.This article makes a summary about the growth hormone receptor expression and function as well as the signal after receptor to the goal gene adjustment and own adjustment.
3.Progress of clinical medication for esophageal cancer
China Oncology 2001;0(03):-
The combination of chemotherapy,radiotherapy and surgery is the current main strategy for esophageal cancer,and chemotherapy plays a vital role in terms of prolongation of survival and quality of life.The development of new chemotherapeutic agents for the treatment of esophageal cancer has been given much attention in the past.This review summarized the effi cacy and safety of new agents based on clinical evidence and the roles of those agents in the multidisciplinary treatment of esophageal cancer.It also included the progress of molecular targeting therapy for the disease.
4.Progress of the mechanism of positive growth factors on malignancy
Parenteral & Enteral Nutrition 1997;0(03):-
Positive growth factors play an active role in improving host metabolism, and then promote the ability to receive the operation and chemotherapy. However, there are many problems concerning their security. They are able to keep tumor cells survive and proliferate which can increase the number of s-phase cells and the expression of some cancer genes (c-myc, etc). They probably, in theory, enhance the tumor’s response to chemotherapy by increasing the number of proliferating tumor cell. They offer a new insights into tumor’s therapy.
5.Review and Meta-analysis of the ω-3 polyunsaturated fatly acid for cancer cechexia treatment
Shiwei LI ; Huaixing MA ; Suyi LI
Parenteral & Enteral Nutrition 2017;24(1):28-32
Objective:To explore the clinical value of PUFA in the treatment of cancer cachexia,meta-analysis and systematic evaluation of literature was applied.Methods:According to the inclusion criteria,PubMed/MEDLINE,EMBASE and the Cochrane Central Register of Controlled TriMs for randomized controlled trims that compared PUFA treatments with placebo or no treatment in cancer cachexia were searched.Outcomes of interest were effects on weight,appetite,the level of CRP and IL-6,the composition of lean body mass and the quality of life.Results:Finally,16 articles were included in the analysis,which reported appetite (6 papers),C-reactive protein (9 papers),IL-6 (5 papers),lean tissue weight (7 papers) and quality of life assessment (7 papers),respectively.Conclusion:PUFAs for the treatment of cancer cachexia plays an irreplaceable role.The body weight,appetite,inflammation index and quality of life can be significantly improved,and the patients can tolerated the addition of PUFA during the treatment.
6.Effects of recombinant human growth hormone on tumor growth and access relevant to Janus kinase 2-signal transducer and activator of transcription 3 of human gastric carcinoma xenografts in nude mice
Ming QUAN ; Peng CAO ; Suyi LI
Chinese Journal of Clinical Nutrition 2011;19(3):171-177
Objective To investigate the effects of recombinant human growth hormone (rhGH) on tumor growth and tumor angiogenesis factor relevant to Janus kinase 2-signal transducer and activator of transcription 3 of human gastric carcinoma xenografts in nude mice with different expressions of growth hormone receptor (GHR).Methods Immunocytochemical method was used to pick out one GHR-positive and one GHR-negative cell line. The cells were subcutaneously injected into 26 nude mice separately, then the patterns of xenografts in nude mice with different expressions of GHR were established. The nude mice bearing two different kinds of human gastric caicinoma were equally randomized into control group, low-dose rhGH group, and high-dose rhGH group,and were treated with drugs for 14 days. Changes of tumor volumes and body weight of nude mice were record. The protein and mRN A expressions of tumor angiogenesis factor in tumor tissue were detected by RT-PCR and Western blot, respectively. Results GHR was highly expressed in SGC-7901 celk but negative in MKN-45 cells. For nude mice bearing GHR+ SGC-7901 xenografts, the tumor volumes were significantly larger in low-dose rhGH group [(1. 141 ±0. 234) cm3] and high-dose rhGH group [(2. 106 ±0. 260) cm3] than in control group [(0.612±0. 156) cm3] (P = 0. 034, P = 0. 001), and the high-dose rhGH group revealed greater effect (P =0. 043 ). Body weight was not significantly different among three groups. Compared with the control group, the mRNA expressions of tumor angiogenesis factor were significantly increased in low-does rhGH group, and the P values of GHR, Janus kinase 2, signal transducer and activator of transcription 3, vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1α (HIF-1α), fibroblast growth factor, and matrix metalloproteinases-2 (MMP-2) was 0.001, 0.011, 0.042, 0.045, 0.040, 0.002, and 0.003, respectively; however, the high-does rhGH group did not show the greater effects. The protein expressions were significantly increased in low-does rhGH group, and the P value of phosphorylation-signal transducer and activator of transcription 3, signal transducer and activator of transcription 3, VEGF, HIF-1α, and MMP-2 was 0. 015, 0.003, 0.010, 0.008,and 0. 005, respectively; furthermore, the high-does group revealed the further greater effects, and the P value of VEGF, HIF-1α, and MMP-2 was 0.012, 0.025, and 0.046, respectively. On the contrary, for nude mice bearing GHR- MKN-45 xenografts, the body weights of low-dose rhGH group [(24.94 ±0. 517) g] and high-dose rhGH group [(26.97 ±0.686) g] were significantly higher than that of control group [(22.78 ±0.418) g] (P =0. 040, P = 0.012 ) , while tumor growth as well as the expressions of mRNA and protein of tumor angiogenesis factor in tumor tissue were not significantly different Conclusions rhGH can promote tumor growth and up-regulate the expression of tumor angiogenesis factor in the GHR-highly-expressed SGC-7901 xenograft tumor model; However,such effects do not exist in GHR-negatively-expressed MKN-45 xenograft tumor model. The existence of GHR may be a key target by which rhGH influences the tumor growth and the expressions of tumor angiogenesis factor, which is probably achieved through Janus kinase 2-signal transducer and activator of transcription 3 activation.
7.The effect of tetrandrine on proliferation and apoptosis of human liver cancer cell line 7402
Wenying DENG ; Xinchen SUN ; Suyi LI
Journal of Medical Postgraduates 2004;0(02):-
Objective:To investigate the anti-tumor effect of tetrandrine on human liver cancer cell line 7402 in vitro.Effects of tetrandrine on proliferation and apoptosis of human liver cancer cell 7402 were observed.Methods:The effects of tetrandrine on proliferation of 7402 cells was observed by MTT assay and clonogenic assay.Apoptosis was observed by acridine orange(AO)/ethidium bromide(EB) Fluorescent staining?DNA gel electrophoresis and flow cytometry,and the expression of apoptosis related gene was analyzed by immunohistochemical staining method.Results:Tetrandrine inhibits the proliferation of 7402 cells in a dose dependent manner and induces apoptosis.Immunohistochemical staining showed that the expression of Bcl-2 was decreased and the expression of Bax was increasd in 7402 cells treated with tetrandrine.Conclusion:Tetrandrine inhibits the proliferation of 7402 in the dose dependent manner,and induces apoptosis.The antitumor effect of tetrandrine may be due to the regulation of the expressions of Bcl-2 and Bax.
8.Study on the effect of growth hormone and chemotherapy in tumor bcaring micc
Lin WANG ; Suyi LI ; Fangfang SHI
Parenteral & Enteral Nutrition 2004;0(05):-
Objective:To study the effect of recombinant human growth hormone(rhGH) and its combination with chemotherapy(5-FU) in tumor bearing mice.Methods:Hepatic metastases model were established in 615 mice by splenic injection of proventriculus squamous carcinoma cell(MFC).Among them,sixty mice were divided randomly into 6 groups(ten per group): control(NS),GH1,GH2,flurouracil(5-FU),flurouracil plus rhGH(GH1+5-FU) and flurouracil plus rhGH(GH2+5-FU).Body weights were measured every week.On the 28~(th) day,animals in each group were executed.The weight of body and liver was measured,and cell cycle of tumor DNA was determined by flow cytometry(FCM). Other 48 animals were divided randomly into 6 groups(eight per group) and treated with the same methods as above.They were fed till death to observe survival time. Results:Body weights in the GH1+(5-FU) and the GH2+5-FU group were increased than that of control group(P
9.Analysis on epidemiological features of measles from 2004 to 2008 in Inner Mongonlia
Shuqin DUAN ; Bin LI ; Suyi GU
Chinese Journal of Disease Control & Prevention 2009;0(01):-
Objective To understand the epidemic feature of measles in Inner Mongolia from 2004 to 2008 so as to provide scientific evidence for measles control.Methods Descriptive epidemiological analysis was conducted on the epidemiology of measles from 2004 to 2008 based on the data collected from the regular report system of infectious diseases and annual statistics of measles.Results 11 880 cases were reported in Inner Mongolia from 2004 to 2008 and the average annual incidence was 9.94/100 thousand.The incidence was 14.96/100 thousand in 2005,when the incidence was the highest.There was a difference in the incidence in different years (P
10.Effects of recombinant human growth hormone combined with fluorouracil on GHR~(2+) or GHR~+ human gastric cancer cell lines in vitro
Fangfang SHI ; Suyi LI ; Qi SHAO
Parenteral & Enteral Nutrition 2004;0(05):-
0.05).Conclusion: rhGH can stimulate the growth of GHR2+ tumor cell lines such as SGC-7901 and weaken the inhibitory effect of 5-FU on GHR2+ tumor cells.However,such effect was not remarked for GHR+ tumor cells in vitro.